Jordan T. Moore
Ohio State University
8 Papers
2 Citations
Jordan T. Moore is an academic researcher from Ohio State University. The author has contributed to research in topics: Myeloid-derived Suppressor Cell & Tumor progression. The author has an hindex of 3, co-authored 8 publications.
Chat about Author
Papers
Topical tissue nano-transfection mediates non-viral stroma reprogramming and rescue
Daniel Gallego-Perez,Durba Pal,Subhadip Ghatak,Veysi Malkoc,Natalia Higuita-Castro,Surya Gnyawali,Lingqian Chang,Wei Ching Liao,Junfeng Shi,Mithun Sinha,Kanhaiya Singh,Erin Steen,Alec Sunyecz,Richard Stewart,Jordan T. Moore,Thomas Ziebro,Robert Northcutt,Michael L. Homsy,Paul Bertani,Wu Lu,Sashwati Roy,Savita Khanna,Cameron Rink,Vishnu Baba Sundaresan,Jose Otero,L. James Lee,Chandan K. Sen +26 more
TL;DR: A novel yet simple-to-implement non-viral approach to topically reprogram tissues through a nanochannelled device validated with well-established and newly developed reprogramming models of induced neurons and endothelium, respectively is reported.
Nanotransfection-based vasculogenic cell reprogramming drives functional recovery in a mouse model of ischemic stroke.
Luke R. Lemmerman,Maria H.H. Balch,Jordan T. Moore,Diego Alzate-Correa,Maria Angelica Rincon-Benavides,Ana Salazar-Puerta,Surya Gnyawali,Hallie Harris,William Lawrence,Lilibeth Ortega-Pineda,Lauren Wilch,Ian B. Risser,Aidan J. Maxwell,Silvia Duarte-Sanmiguel,Daniel J. Dodd,Gina P. Guio-Vega,Gina P. Guio-Vega,Dana M. McTigue,W. David Arnold,Shahid M Nimjee,Chandan K. Sen,Savita Khanna,Cameron Rink,Natalia Higuita-Castro,Daniel Gallego-Perez +24 more
TL;DR: In this article, the authors used fibroblasts nanotransfected with Etv2, Foxc2, and Fli1 (EFF) to drive reprogramming-based vasculogenesis, intracranially.
41
Nanochannel-Based Poration Drives Benign and Effective Nonviral Gene Delivery to Peripheral Nerve Tissue
Jordan T. Moore,Christopher G. Wier,Luke R. Lemmerman,Lilibeth Ortega-Pineda,Daniel J. Dodd,William Lawrence,Silvia Duarte-Sanmiguel,Kavya Dathathreya,Ludmila Diaz-Starokozheva,Hallie Harris,Chandan K. Sen,Ian L. Valerio,Natalia Higuita-Castro,Natalia Higuita-Castro,William Arnold,Stephen J. Kolb,Daniel Gallego-Perez,Daniel Gallego-Perez +17 more
- 16 Sep 2020
TL;DR: The results indicate that TNT can be a powerful platform nanotechnology for localized nonviral gene delivery to nerve tissue, in vivo, and the deployment of reprogramming‐based cell therapies for nerve repair/regeneration.
16
In Situ Deployment of Engineered Extracellular Vesicles into the Tumor Niche via Myeloid-Derived Suppressor Cells.
Silvia Duarte-Sanmiguel,Ana Panic,Daniel J. Dodd,Ana Salazar-Puerta,Jordan T. Moore,William Lawrence,Kylie G. Nairon,Carlie Francis,Natalie Zachariah,William McCoy,Rithvik Turaga,Aleksander Skardal,William E. Carson,Natalia Higuita-Castro,Daniel Gallego-Perez +14 more
TL;DR: In this article, non-viral transfection of myeloid-derived suppressor cells (MDSCs) can be leveraged to drive targeted release of engineered EVs that can modulate transfer and overexpression of therapeutic anticancer genes in tumor cells and tissue.
15
Early Intervention in Ischemic Tissue with Oxygen Nanocarriers Enables Successful Implementation of Restorative Cell Therapies.
Ludmila Diaz-Starokozheva,Devleena Das,Xiangming Gu,Jordan T. Moore,Luke R. Lemmerman,Ian L. Valerio,Heather M. Powell,Heather M. Powell,Natalia Higuita-Castro,Michael R. Go,Andre F. Palmer,Daniel Gallego-Perez +11 more
TL;DR: Results indicate that PolyHb and TNT technologies could potentially be synergistically deployed and used as early intervention measures to combat severe tissue ischemia.
11